Review article · 2021 · Open access
Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges
Current Protocols, 1(3), e88 · Published 1 March 2021 · DOI 10.1002/cpz1.88
In brief
“Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges” is a 2021 review article by Marinna Madrid and 3 co-authors, published in Current Protocols. OpenAlex counts 126 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Current Protocols.
- Citations
- 126
- Most cited in
- 2023 (35)
- Field-weighted impact
- 1.89
- References
- 158
- Authors
- 4
Abstract
The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as a starting material for autologous, or patient-specific, stem cell-based therapies. Since the first publications describing the generation of iPSCs from human tissue in 2007, a Phase I/IIa clinical trial testing an autologous iPSC-derived cell therapy has been initiated in the U.S., and several other autologous iPSC-based therapies have advanced through various stages of development. Three single-patient in-human transplants of autologous iPSC-derived cells have taken place worldwide. None of the patients suffered serious adverse events, despite not undergoing immunosuppression. These promising outcomes support the proposed advantage of an autologous approach: a cell therapy product that can engraft without the risk of immune rejection, eliminating the need for immunosuppression and the associated side effects. Despite this advantage, there are currently more allogeneic than autologous iPSC-based cell therapy products in development due to the cost and complexity of scaling out manufacturing for each patient. In this review, we highlight recent progress toward clinical translation of autologous iPSC-based cell therapies. We also highlight technological advancements that would reduce the cost and complexity of autologous iPSC-based cell therapy production, enabling autologous iPSC-based therapies to become a more commonplace treatment modality for patients. © 2021 The Authors.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Madrid, M., Sumen, C., Aivio, S., & Saklayen, N. (2021). Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges. Current Protocols, 1(3), e88. https://doi.org/10.1002/cpz1.88
MLA 9
Madrid, Marinna, et al. “Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges.” Current Protocols, vol. 1, no. 3, 2021, p. e88. https://doi.org/10.1002/cpz1.88.
Chicago
Madrid, Marinna, Cenk Sumen, Suvi Aivio, and Nabiha Saklayen. 2021. “Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges.” Current Protocols 1 (3): e88. https://doi.org/10.1002/cpz1.88.
Harvard
Madrid, M. et al. (2021) ‘Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges’, Current Protocols, 1(3), p. e88. doi:10.1002/cpz1.88.
IEEE
M. Madrid, C. Sumen, S. Aivio, and N. Saklayen, “Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges,” Current Protocols, vol. 1, no. 3, p. e88, 2021, doi: 10.1002/cpz1.88.
BibTeX
@article{madrid2021autologous,
title = {{Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges}},
author = {Madrid, Marinna and Sumen, Cenk and Aivio, Suvi and Saklayen, Nabiha},
journal = {Current Protocols},
year = {2021},
volume = {1},
number = {3},
pages = {e88},
doi = {10.1002/cpz1.88},
url = {https://doi.org/10.1002/cpz1.88}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 1 | |
| 2021 | 2 | |
| 2022 | 15 | |
| 2023 | 35 | |
| 2024 | 27 | |
| 2025 | 32 | |
| 2026 | 14 |
Its field-weighted citation impact is 1.89: it has been cited 1.89 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- clinical translation
- patient-specific cell therapy
- cell therapy manufacturing
- immunosuppression-free transplantation
- immune rejection
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Madrid, M., Sumen, C., Aivio, S., & Saklayen, N. (2021). Autologous Induced Pluripotent Stem Cell–Based Cell Therapies: Promise, Progress, and Challenges. Current Protocols, 1(3), e88. https://doi.org/10.1002/cpz1.88
How many times has this paper been cited?
126 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Current Protocols: sign in and open the PDF from this page.
Who wrote this paper?
Marinna Madrid, Cenk Sumen, Suvi Aivio, Nabiha Saklayen.
What is the DOI of this paper?
10.1002/cpz1.88, permanently at https://doi.org/10.1002/cpz1.88. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.